607 related articles for article (PubMed ID: 26063715)
21. Vancomycin-resistant Enterococcus bacteremia: an evaluation of treatment with linezolid or daptomycin.
Twilla JD; Finch CK; Usery JB; Gelfand MS; Hudson JQ; Broyles JE
J Hosp Med; 2012 Mar; 7(3):243-8. PubMed ID: 22076962
[TBL] [Abstract][Full Text] [Related]
22. Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid?
Mave V; Garcia-Diaz J; Islam T; Hasbun R
J Antimicrob Chemother; 2009 Jul; 64(1):175-80. PubMed ID: 19423543
[TBL] [Abstract][Full Text] [Related]
23. Systematic review and meta-analysis of linezolid and daptomycin for treatment of vancomycin-resistant enterococcal bloodstream infections.
Whang DW; Miller LG; Partain NM; McKinnell JA
Antimicrob Agents Chemother; 2013 Oct; 57(10):5013-8. PubMed ID: 23896468
[TBL] [Abstract][Full Text] [Related]
24. Clinical characteristics and treatment outcomes of vancomycin-resistant Enterococcus faecium bacteremia.
Ye JJ; Shie SS; Cheng CW; Yang JH; Huang PY; Wu TS; Lee MH; Huang CT
J Microbiol Immunol Infect; 2018 Dec; 51(6):705-716. PubMed ID: 29046248
[TBL] [Abstract][Full Text] [Related]
25. Vancomycin-resistant enterococci infection and predisposing factors for infection and mortality in patients with acute leukaemia and febrile neutropenia.
Kirkizlar TA; Akalin H; Kirkizlar O; Ozkalemkas F; Ozkocaman V; Kazak E; Ozakin C; Bulbul EN; Ozboz ES; Ali R
Leuk Res; 2020 Dec; 99():106463. PubMed ID: 33130331
[TBL] [Abstract][Full Text] [Related]
26. Risk factors for mortality after linezolid treatment of vancomycin-resistant Enterococcus bloodstream infection.
Huang ST; Yang JL; Lin CY; Huang SH; Wang JT; Chuang YC; Chen YC; Chang SC
Int J Infect Dis; 2023 Apr; 129():96-102. PubMed ID: 36736576
[TBL] [Abstract][Full Text] [Related]
27. Therapeutics for Vancomycin-Resistant Enterococcal Bloodstream Infections.
Cairns KA; Udy AA; Peel TN; Abbott IJ; Dooley MJ; Peleg AY
Clin Microbiol Rev; 2023 Jun; 36(2):e0005922. PubMed ID: 37067406
[TBL] [Abstract][Full Text] [Related]
28. The importance of adjusting for enterococcus species when assessing the burden of vancomycin resistance: a cohort study including over 1000 cases of enterococcal bloodstream infections.
Kramer TS; Remschmidt C; Werner S; Behnke M; Schwab F; Werner G; Gastmeier P; Leistner R
Antimicrob Resist Infect Control; 2018; 7():133. PubMed ID: 30459945
[TBL] [Abstract][Full Text] [Related]
29. Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bacteremia.
Balli EP; Venetis CA; Miyakis S
Antimicrob Agents Chemother; 2014; 58(2):734-9. PubMed ID: 24247127
[TBL] [Abstract][Full Text] [Related]
30. Vancomycin-resistant Enterococcus bacteremia in a child with acute myeloid leukemia: successful treatment with daptomycin.
Büyükcam A; Karadağ Öncel E; Özsürekçi Y; Cengiz AB; Kuşkonmaz B; Sancak B
Arch Argent Pediatr; 2016 Dec; 114(6):e432-e435. PubMed ID: 27869427
[TBL] [Abstract][Full Text] [Related]
31. [Treatment of vancomycin-resistant enterococcal infections].
Lund LC; Holzknecht BJ; Justesen US
Ugeskr Laeger; 2018 Apr; 180(16):. PubMed ID: 29690991
[TBL] [Abstract][Full Text] [Related]
32. Comparison of linezolid and daptomycin for the treatment of vancomycin-resistant enterococcal bacteremia.
Narayanan N; Rai R; Vaidya P; Desai A; Bhowmick T; Weinstein MP
Ther Adv Infect Dis; 2019; 6():2049936119828964. PubMed ID: 30792858
[TBL] [Abstract][Full Text] [Related]
33. Observational study of the epidemiology and outcomes of vancomycin-resistant Enterococcus bacteraemia treated with newer antimicrobial agents.
McKinnell JA; Patel M; Shirley RM; Kunz DF; Moser SA; Baddley JW
Epidemiol Infect; 2011 Sep; 139(9):1342-50. PubMed ID: 21073764
[TBL] [Abstract][Full Text] [Related]
34. Epidemiology, treatment and outcomes of bloodstream infection due to vancomycin-resistant enterococci in cancer patients in a vanB endemic setting.
Xie O; Slavin MA; Teh BW; Bajel A; Douglas AP; Worth LJ
BMC Infect Dis; 2020 Mar; 20(1):228. PubMed ID: 32188401
[TBL] [Abstract][Full Text] [Related]
35. Vancomycin-resistant enterococcal bacteraemia and daptomycin: are higher doses necessary?
King EA; McCoy D; Desai S; Nyirenda T; Bicking K
J Antimicrob Chemother; 2011 Sep; 66(9):2112-8. PubMed ID: 21697178
[TBL] [Abstract][Full Text] [Related]
36. Treatment Considerations for CNS Infections Caused by Vancomycin-Resistant
Lee BJ; Vu BN; Seddon AN; Hodgson HA; Wang SK
Ann Pharmacother; 2020 Dec; 54(12):1243-1251. PubMed ID: 32506921
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the treatment of methicillin-resistant Staphylococcus aureus bacteremia.
Usery JB; Vo NH; Finch CK; Cleveland KO; Gelfand MS; Self TH
Am J Med Sci; 2015 Jan; 349(1):36-41. PubMed ID: 25233042
[TBL] [Abstract][Full Text] [Related]
38. Treatment considerations in vancomycin-resistant enterococcal bacteremia: daptomycin or linezolid? A review.
Shukla BS; Gauthier TP; Correa R; Smith L; Abbo L
Int J Clin Pharm; 2013 Oct; 35(5):697-703. PubMed ID: 23893061
[TBL] [Abstract][Full Text] [Related]
39. Survival of Patients With Vancomycin-Resistant Enterococcus faecium Bacteremia Treated With Conventional or High Doses of Daptomycin or Linezolid Is Associated With the Rate of Bacterial Clearance.
Chuang YC; Lin HY; Chen PY; Lin CY; Chen YC; Wang JT; Chang SC
Crit Care Med; 2018 Oct; 46(10):1634-1642. PubMed ID: 29957707
[TBL] [Abstract][Full Text] [Related]
40. Daptomycin therapy for invasive Gram-positive bacterial infections in children.
Ardura MI; Mejías A; Katz KS; Revell P; McCracken GH; Sánchez PJ
Pediatr Infect Dis J; 2007 Dec; 26(12):1128-32. PubMed ID: 18043450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
